Breaking Finance News

Chardan Capital disclosed Biocept Inc (NDAQ:BIOC), bumping down its price target to $1.50 earlier today

Stating a potential upside of 1.38%, Chardan Capital lowered the target price of Biocept Inc (NDAQ:BIOC) to $1.50

Previously on Friday June 02, 2017, Chardan Capital released a statement about Biocept Inc (NDAQ:BIOC) increased the target price from $0.00 to $2.50. At the time, this indicated a possible upside of 0.62%.

Just yesterday Biocept Inc (NDAQ:BIOC) traded 0.00% even at $0.63. Biocept Inc’s 50-day moving average is $1.21 and its 200-day moving average is $1.38. The last stock price is down -29.71% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.02% over the same time period. 339,362 shares of BIOC traded hands, up from an average trading volume of 295,600

Recent Performance Chart

Biocept Inc (NDAQ:BIOC)

Biocept Inc has 52 week low of $0.74 and a 52 week high of $3.39 and has a market capitalization of $0.

Brief Synopsis On Biocept Inc (NDAQ:BIOC)

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.